Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.

Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.

<h4>Aim</h4>Alterations in microbial composition of gut microbiota due to antibiotics (ATB) may lead to resistance to immune checkpoint inhibitors (ICIs). This study aimed to assess the impact of ATB use on therapeutic response in patients with hepatocellular carcinoma (HCC) receiving at...

Full description

Bibliographic Details
Main Authors: Kazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, Akira Doi, Yuki Tahata, Kazuyoshi Ohkawa, Masahide Oshita, Masanori Miyazaki, Takayuki Yakushijin, Yasutoshi Nozaki, Kengo Matsumoto, Satoshi Tanaka, Akira Kaneko, Sadaharu Iio, Takatoshi Nawa, Yukinori Yamada, Naoki Morishita, Takeo Usui, Naoki Hiramatsu, Yoshinori Doi, Mitsuru Sakakibara, Kazuho Imanaka, Yuichi Yoshida, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2023-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0281459

Internet

https://doi.org/10.1371/journal.pone.0281459

Similar Items